Advertisement

Topics

Hemispherx Biopharma Company Profile

14:58 EDT 23rd March 2019 | BioPortfolio

Hemispherx Biopharma, Inc. has devoted nearly three decades to exploring, understanding, and mastering the mechanism of RNA technology. The Company's longevity as a biomedical research and drug development institution, coupled with its record of tremendous enduring scientific achievement is evidence of Hemispherx’s long-term commitment to this promising new class of drugs and to bring new therapeutic choices to the global community.



Using nucleic acid technologies to develop therapeutic products for the treatment of viral disease and certain cancers, the company has pioneered a new class of specifically-configured ribonucleic acid (RNA) which targets the treatment of Chronic Fatigue Syndrome (CFS), HIV associated disorders, chronic hepatitis B & C infection and cancers which include kidney cancer and metastatic malignant melanoma. Hemispherx with its predecessor, HEM Pharmaceuticals has nearly 30 years of RNA technology and is believed to be the only biotechnology company using nucleic acid drug methodology targeting the body's natural anti-viral defense system.

Location

One Penn Center
1617 JFK Blvd., 6th Floor
Philadelphia
PA
19103
United States of America

Contact

Phone: (215) 988-0080
Fax: (215) 988-1739
Email: info@hemispherx.net


News Articles [1028 Associated News Articles listed on BioPortfolio]

Hemispherx Biopharma Announces First Large Ampligen Shipment to a Clinical Site

Hemispherx Biopharma (NYSE:HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, shipped 720 vials of Ampligen to the Myalgic Encephalomye...

Hemispherx Biopharma Announces Advancement in Expanded Access Program for Ampligen

Hemispherx Biopharma (NYSE:HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, shipped 325 recently manufactured vials of Ampligen to th...

Hemispherx Biopharma updates on current trials, gears up to begin 5 more

Hemispherx Biopharma Inc (NYSE American:HEB) CEO Tom Equels updates Proactive Investors on its US trials with cancer drug candidate Ampligen, and says the biopharma is initiating five additional Amp...

Hemispherx Biopharma posts reminder of deadline for $8M rights issue

Ownership of Hemispherx stock must occur on February 12 to allow for participation in the $8 million rights offering

Hemispherx Biopharma Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center

Hemispherx Biopharma (NYSE:HEB) announces the signing of a clinical trial agreement with Roswell Park Comprehensive Cancer Center to evaluate Ampligen in combination with checkpoint inhibitors (CPIs)...

Hemispherx Biopharma started with a Buy rating at Ascendiant Capital Markets

In a note to investors, the analyst says the biopharma has made significant advances with its oncology program for its therapy Ampligen

Hemispherx Biopharma advances expanded access program for its therapy Ampligen

Hemispherx BioPharma Inc (NYSEAmerican:HEB) CEO Tom Equels tells Proactive Investors the Florida-based immunopharma company has shipped more than 300 recently manufactured vials of Ampligen to the M...

Hemispherx Clarifies Apple IOS12 Stocks App 'No Recent Stories' Misinformation

CUPERTINO (dpa-AFX) - Hemispherx Biopharma Inc. (HEB) said that it continues to work with Apple and other affected parties for a solution to correct Apple iOS12 Stocks Application misinformation a...

Drugs and Medications [9 Associated Drugs and Medications listed on BioPortfolio]

Alferon [hemispherx biopharma, inc]

NA

Yupelri [the ritedose corporation]

Yupelri (Revefenacin) Inhalation Solution 175 mcg/3 mL

Keveyis [strongbridge us inc.]

These highlights do not include all the information needed to use KEVEYIS safely and effectively. See full prescribing information for KEVEYIS. KEVEYIS (dichlorphenamide) tablets, for oral use Initial...

Macrilen [strongbridge u.s. inc]

These highlights do not include all the information needed to use MACRILEN safely and effectively. See full prescribing information for MACRILEN.MACRILEN (macimorelin) for oral solution Initial U.S. A...

Recombinate [baxter healthcare corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

PubMed Articles [4 Associated PubMed Articles listed on BioPortfolio]

Biopharma dealmaking in 2018.

Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation.

At the turn of the century, the pharmaceutical industry began a transition toward a focus on oncology, rare diseases, and other areas of high unmet need that required a new, more complex approach to d...

Bicyclic bis-heteroaryl derivatives as inhibitors of the α-synuclein protein: a patent evaluation of WO2018138088A1.

Neurodegenerative diseases commonly present misfolding and aggregation of one or more proteins, including α-synuclein, β-amyloid and tau. Several research efforts have been made to develop therapeut...

AQB-565 shows promise in preclinical testing in the model of epileptic spasms during infancy: Head-to-head comparison with ACTH.

Epileptic spasms during infancy (infantile spasms) represent a serious treatment and social problem despite their rare occurrence. Current treatments include hormonal therapy (adrenocorticotropin-ACTH...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes

ARRY-403 is an investigational new drug being developed by Array BioPharma Inc. for treating Type 2 diabetes. The purpose of this study is to test the safety (potential side effects) and ...

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Companies [150 Associated Companies listed on BioPortfolio]

Hemispherx Biopharma

Hemispherx Biopharma, Inc. has devoted nearly three decades to exploring, understanding, and mastering the mechanism of RNA technology. The Company's longevity as a biomedical research and drug develo...

SAFE-BioPharma Association

SAFE-BioPharma Association (www.safe-biopharma.org) is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the ...

Kedrion Biopharma, Inc.

Kedrion Biopharma is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and pre...

Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the Company, visit http://www.genesis-b...

SAFE-BioPharma Association, LLC

As part of the National Health Information Sharing and Analysis Center (NH-ISAC), SAFE-BioPharma Association, LLC [www.safe-biopharma.org] provides global, high-assurance identity...

More Information about "Hemispherx Biopharma" on BioPortfolio

We have published hundreds of Hemispherx Biopharma news stories on BioPortfolio along with dozens of Hemispherx Biopharma Clinical Trials and PubMed Articles about Hemispherx Biopharma for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Hemispherx Biopharma Companies in our database. You can also find out about relevant Hemispherx Biopharma Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Sleep Disorders
Sleep disorders disrupt sleep during the night, or cause sleepiness during the day, caused by physiological or psychological factors. The common ones include snoring and sleep apnea, insomnia, parasomnias, sleep paralysis, restless legs syndrome, circa...


Corporate Database Quicklinks



Searches Linking to this Company Record